Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature.
Judith Stangl-KremserAndres Ricaurte-FajardoKritika SubramanianJoseph R OsborneMichael SunScott TagawaNeil H BanderPublished in: The Prostate (2023)
225Ac-PSMA RLT is an experimental treatment for men with mCRPC. There is limited data available from high-quality trials but so far PSMA-targeted RLT has demonstrated a low morbidity profile. Our review revealed that there is a possible decrease in efficacy of targeted alpha-particle therapy if individuals previously were exposed to 177Lu-PSMA RLT. However, the level of evidence is low. The underlying mechanism by which 177Lu-PSMA RLT might trigger possible radioresistance as well as randomized controlled trials are required to establish the therapeutic efficacy and safety of 225-Ac-PSMA RLT in men refractory to 177Lu-PSMA RLT. This article is protected by copyright. All rights reserved.
Keyphrases
- pet ct
- pet imaging
- prostate cancer
- randomized controlled trial
- positron emission tomography
- cancer therapy
- systematic review
- clinical trial
- radical prostatectomy
- computed tomography
- single cell
- electronic health record
- oxidative stress
- bone marrow
- dna damage
- deep learning
- dna damage response
- dna repair
- artificial intelligence
- data analysis
- cancer stem cells